Oral Anticoagulants and Renal Impairment: The Convoluting Dilemma

Affiliations

¹ Department of Neurology, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204; USA. Electronic address: vserebr1@jhmi.edu.

Comment

Victor Serebruany. EBioMedicine. 2016 Jun.

. 2016 Jun:8:21-22.

doi: 10.1016/j.ebiom.2016.04.027. Epub 2016 Apr 27.

¹ Department of Neurology, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204; USA. Electronic address: vserebr1@jhmi.edu.

No abstract available

Comment on

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials.
Proietti M, Lane DA, Lip GYH. Proietti M, et al. EBioMedicine. 2016 Jun;8:309-316. doi: 10.1016/j.ebiom.2016.04.013. Epub 2016 Apr 19. EBioMedicine. 2016. PMID: 27428440 Free PMC article.

1. De Caterina R., Husted S., Wallentin L. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC working group on thrombosis — task force on anticoagulants in heart disease. Thromb. Haemost. 2016;115:685–711. - PubMed
1. Verheugt F.W., Granger C.B. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015;386(9990):303–310. - PubMed
1. Blann A.D., Lip G.Y. Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores inpredicting MACE in AF. Thromb. Haemost. 2015;113:1155–1157. - PubMed
1. Ng K.P., Edwards N.C., Lip G.Y., Townend J.N., Ferro C.J. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am. J. Kidney Dis. 2013;62:615–632. - PubMed
1. Shen J.I., Turakhia M.P., Winkelmayer W.C. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr. Opin. Nephrol. Hypertens. 2012;21:600–606. - PMC - PubMed